Kilitch Drugs has announced a board meeting to approve the financial results for the quarter and half-year.

Q4FY25 standalone PAT surged 212% YoY to Rs 11.37 Cr, with revenue up 44% to Rs 181.59 Cr.

Consolidated PAT rose 178% YoY to Rs 10.22 Cr.

FY25 standalone PAT grew 77% YoY to Rs 31.16 Cr, backed by a 38% revenue increase.

Expansion continues with a new greenfield project in Pen, Maharashtra, boosting manufacturing capacity and global supply strength.